Search for biomarkers predicting the effect of drug intervention on coronary artery calcification in patients with non-dialysis CKD

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K23997
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0904:Internal medicine of the bio-information integration and related fields
• Research Institution: Osaka University
• Principal Investigator: Doi Yohei 大阪大学, 医学部附属病院, 医員 (30846382)
• Project Period (FY): 2019-08-30 – 2021-03-31
• Keywords: 冠動脈石灰化 / 慢性腎臓病

Outline of Final Research Achievements

In this study, osteoprotegerin (OPG), indoxyl sulfate (IS), and paracresyl sulfate (PCS) concentrations were measured at baseline and after 1 year using stored specimens from a 2 by 2 factorial randomized controlled trial examining the effect of magnesium (Mg) and AST120 on the inhibition of coronary artery calcification (CAC) progression in patients with chronic kidney disease stage 3 and 4. There were no significant changes in serum OPG, IS, or PCS concentrations at 1 year between the groups with or without Mg or AST120. Baseline serum OPG, IS, or PCS concentrations did not modify the effects of Mg or AST120 on the change in CAC score at 2 years.

Free Research Field

CKD-MBD

Academic Significance and Societal Importance of the Research Achievements

本研究から、保存期慢性腎臓病患者において日本で臨床的に用いられるAST120 6g/日では、尿毒症物質である血中インドキシル硫酸（IS）、パラクレシル硫酸（PCS）の濃度を低下させることができないことが示唆された。基礎研究ではISやPCSが直接的に血管石灰化を惹起すると報告されており、血中IS、PCSを低下させる方法や意義についてさらなる研究が必要である。